Biogen Inc. has announced that its applications for a higher dose regimen of nusinersen, an investigational treatment for spinal muscular atrophy $(SMA)$, are currently under regulatory review in the U.S., Europe, Japan, and other global markets. This new regimen, evaluated in Part C of the DEVOTE trial, involves a more rapid loading of two 50 mg doses 14 days apart, followed by a maintenance dose of 28 mg every four months. The ongoing review aims to assess the potential benefits of this higher dose regimen in improving motor function in individuals with SMA. Biogen remains committed to advancing treatment options in the evolving SMA landscape.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.